Does COVID-19 infection (and use of Paxlovid or other antivirals) affect your decision on timing of maintenance anti-CD20 mAb therapy (eg Rituxan, Ocrevus) in patients with multiple sclerosis?

Topics: Neurology • Neuro-immunology

Answer from: at Academic Institution

There have been several publications addressing B-cell therapies in general and severity of COVID infection, see Simpson-Yap et al., PMID 34610987 for a recent analysis from a large international dataset.Overall, while there is an increased risk for hospitalization and ICU admission with Ocrevus com...

Related Questions